October 15 & WORKSHOP ON DRUG DISCOVERY AND INFECTIOUS DISEASE. IMéRA, Maison des astronomes, Marseille

Size: px

Start display at page:

Download "October 15 & WORKSHOP ON DRUG DISCOVERY AND INFECTIOUS DISEASE. IMéRA, Maison des astronomes, Marseille"

Clifford Lloyd
6 years ago
Views:

October 15 & 16 2015 WORKSHOP ON DRUG DISCOVERY AND INFECTIOUS DISEASE IMéRA, Maison des astronomes, Marseille Organizing committee Philippe HALFON Hôpital Européen, laboratoire

fr Marc BOURLIERE Head of Department of Hepato-Gastro-enterology, Hopital Saint-Joseph, Marseille ; email : mbourliere@hopital-saint-joseph.

service d anatomo-pathologique, Hôpital Beaujon, AP-HP Marc BOURLIERE Head of Department of Hepato-Gastro-enterology, Hopital Saint-Joseph, Marseille Jacques BELGHITI Professor of

1 October 15 & WORKSHOP ON DRUG DISCOVERY AND INFECTIOUS DISEASE IMéRA, Maison des astronomes, Marseille Organizing committee Philippe HALFON Hôpital Européen, laboratoire Alphabio, service maladies infectieuses, Marseille ; philippe.halfon@alphabio.fr Marc BOURLIERE Head of Department of Hepato-Gastro-enterology, Hopital Saint-Joseph, Marseille ; mbourliere@hopital-saint-joseph.fr Speakers Tarik ASSELAH Professor of Medicine, service d hépatologie & Head of Viral Hepatitis INSERM UMR1149, Hôpital Beaujon, AP-HP Pierre BEDOSSA Professor of Pathologie, service d anatomo-pathologique, Hôpital Beaujon, AP-HP Marc BOURLIERE Head of Department of Hepato-Gastro-enterology, Hopital Saint-Joseph, Marseille Jacques BELGHITI Professor of Surgery, Haute Autorité de Santé Philippe HALFON Hôpital Européen, laboratoire Alphabio, service maladies infectieuses, Marseille Raymond SCHINAZI Veterans Affairs Medical Center, Atlanta, Georgia, USA. Eric VIVIER Director, Centre d'immunologie de Marseille-Luminy ; Professor of Immunology, Marseille Medical School

2 Thursday 15 October h30-15h40 First Session: Chairs: 15h40-16H10 Introduction: Philippe Halfon Hepatitis B and Philipe Halfon Hepatitis B: current therapy Tarik Asselah 16H10-16H40 Perspectives for an HBV cure Raymond Schinazi 16H40-17H10 Viral resistance: will it be an issue? Philippe Halfon 17h10-17h30 Round Table Friday 16 October 2015 Second session: Perspectives in Therapeutics Chairs: 09H30-10h00 10h00-10H30 Tarik Asselah and Philippe Halfon Cancer Immune-therapy Eric Vivier Cancer stem cells therapy Philippe Halfon 10H30-11h00 HCV drug discovery Raymond Schinazi 11h00-11h30 Third session : Chairs 14h30-15h00 15H00-15H30 15H30-16H00 16h00-16h20 Round Table Future perspectives for liver diseases Liver transplantation : Perspectives Jacques Belghiti HCV future clinical trials Round table Conclusion and Take home messages

Organizing committee Dr. Philippe HALFON: Head of Infectious diseases in Hospital Europeen and head of the Virological department Alphabio laboratory, Marseilles, and.

He received hispharmd degree in 1985 from the University of Marseilles and completed training Virology in Saint Louis Hospital and Institute Pasteur in Paris.

3 Organizing committee Dr. Philippe HALFON: Head of Infectious diseases in Hospital Europeen and head of the Virological department Alphabio laboratory, Marseilles, and. He is appointed as Professor of Medicine at Paris Medical College. He received hispharmd degree in 1985 from the University of Marseilles and completed training Virology in Saint Louis Hospital and Institute Pasteur in Paris. He received his PhD degree in 1993 and post-doctoral training in Virology at McGill University, Montreal, Canada. He received is MD degree from the University of Marseilles and completed training as Infectious Diseases. He has published over 250 peer-reviewed papers and 3 books, and holds 4US patents. Pr Halfon is the founder of several biotechnology companies focusing on antiviral drug discovery and development, and is currently developing one drug in HCV and two innovative drugs in treatment of cancer stem cells. Pr Halfon received award of Tremplin in the Sénat-France France. Dr. Halfon is member on scientist societies and French Agency against AIDS and European Expert for Institutional agency., received his medical degree in 1987 from Marseilles University in Marseile, France. He completed his fellowship training at Marseilles University hospital and in Beaujon University hospital in Paris. He was assistant in Hepatology in Conception University hospital in Marseilles before taking up his current position as head of the Hepato- Gastroenterology department at Hospital Saint Joseph also in Marseilles. Dr Bourlière and his group have participated in hepatitis B and C and HCC clinical trials; His current research focus is the use and development of non invasive biomarkers in hepatitis and the development of new antiviral therapy for hepatitis C. Dr Bourlière has published more than 200 papers or chapters in international journals and books focused on hepatitis B and C. As well as reviewing for many specialist journals, he has served as member of the editorial board of Gastroenterologie, Clinique et Biologique. Dr Bourlière belongs to the French Agency for AIDS and hepatitis research (ANRS) and he heads the ANRS group that coordinates hepatitis clinical therapeutic trials (AC24). He co chair the ANRS group that coordinates hepatitis clinical trial in co infected patients (AC5-24). He belonged to the scientific committee of the HEPATHER cohort. He is also member of several professional societies including the French and European associations for the study of the liver.

Professor Asselah s fields of research include natural history of chronic hepatitis B and C (HCV virology, fibrogenesis, insulin resistance) and clinical trials on new molecules.

4 Speakers Tarik Asselah is a Professor of Medicine and Hepatology at Hôpital Beaujon, Clichy, France, and at the University Paris Diderot, France. He has a medical degree in gastroenterology hepatology and also holds a PhD in virology. Professor Asselah s fields of research include natural history of chronic hepatitis B and C (HCV virology, fibrogenesis, insulin resistance) and clinical trials on new molecules. He also works on gene expression and HCV infection, implications in fibrosis progression and response to treatment. Professor Asselah leads a research group on viral hepatitis at INSERM (UMR 1149, Centre de Recherche sur l Inflammation). He has a particular interest in the treatment of HBV and HCV with new direct-acting antivirals. He has been involved as a principal investigator in several clinical trials of direct-acting antiviral agents for HCV. Professor Asselah is a member of EASL and an expert for the French National Agency for Research on AIDS and Viral Hepatitis (ANRS). He has published more than 170 articles in the field of viral hepatitis with numerous original articles, book chapters and reviews in peerreviewed journals, including Gastroenterology, Hepatology, Blood, Gut and Journal of Hepatology (H-index = 45). Professor Asselah was selected as a rising star in gastroenterology in 2009 by the UEG. He received a prize for his genomic studies on HCV in 2005 from the French Association for the Study of the Liver. Professor Belghiti was born in Casablanca, Morocco in He graduated from the University of Medicine, Paris in 1974, qualified as a surgeon in 1980 and became a Professor of Surgery in He was the Head of the HepatoBilioPancreatic Surgery and Liver Transplantation department in Beaujon Hospital, University of Paris, for 20 years, until In addition Professor Belghiti is the author of more than 70 book chapters and is co-editor of the highly acclaimed specialty reference book, Surgery of the Liver, Biliary Tract and Pancreas edited by Blumgart. In 2014 he was nominated by the President of France to the board of the High Authority for Health, where he chairs the evaluation committee of medical devices. He was recently appointed head of the selection committee for innovative devices. Several associations have benefitted from Professor Belghiti s expertise including as chairman of the scientific committee of the IHPBA, president of E-AHPBA and president of the ILTS (International Liver Transplantation Society). He was responsible for the organisation of the ILTS World Congress in Paris in 2008, as well as the 10th World Congress of the IHPBA in Paris.

Dr. Raymond F. Schinazi is the Frances Winship Walters Professor of Pediatrics and director of the Laboratory of Biochemical Pharmacology at Emory University.

Center for AIDS Research (CFAR). Dr. Schinazi received his D.Sc. (1972) and Ph.D. (1976) in chemistry from the University of Bath, England.

5 Dr. Raymond F. Schinazi is the Frances Winship Walters Professor of Pediatrics and director of the Laboratory of Biochemical Pharmacology at Emory University. He serves as senior research career scientist at the Atlanta Department of Veterans Affairs and director of the Scientific Working Group on Viral Eradication for the NIH-sponsored Emory University Center for AIDS Research (CFAR). Dr. Schinazi received his D.Sc. (1972) and Ph.D. (1976) in chemistry from the University of Bath, England. He has authored over 500 peer-reviewed papers and seven books and holds 92 issued U.S. patents and over 120 non-u.s. national stage patents and patent applications, which have resulted in 12 New Drug Applications. A world leader in nucleoside chemistry, Dr. Schinazi is best known for his pioneering work on HIV and hepatitis C virus (HCV) drugs d4t (stavudine), 3TC (lamivudine), FTC (emtricitabine/emtriva), LdT (telbivudine) and most recently sofosbuvir (Sovaldi), which are now approved by the FDA. He is also the founder of five biotechnology companies, including Pharmasset, Inc. More than 94 percent of HIVinfected individuals in the U.S. on combination therapy take at least one of the drugs he invented, and it is estimated that his work has saved more than three million lives worldwide. Dr. Schinazi served on the Presidential Commission on AIDS and is the recipient of numerous awards, including the 2006 Distinguished Scientist Award from the Hepatitis B Foundation, the Friends of the National Library of Medicine 2013 Distinguished Medical Science Award, the SCRIP 100 Leaders Award in 2014, and the Emory University s 175 History Makers. Dr. Schinazi is internationally recognized as one of the most influential persons in the life science sector. Eric Vivier was trained as a Doctor in Veterinary Medicine and as a PhD in Immunology in Paris. He completed his postdoctoral work at Harvard. He is currently the Director of the Centre d Immunologie de Marseille-Luminy, where he heads the laboratory of «Natural Killer cells and Innate Immunity». He is a Professor at the Marseille Medical School and a Scholar at the Institut Universitaire de France. His work focuses on Natural Killer cells and Innate Lymphoid cells. He is co-founder of Innate-Pharma where he is collaborating to set-up NK cell-based therapies against cancer, such as the anti-kir and anti-nkg2a mabs. Eric Vivier has been elected to the French National Academy of Medicine in 2013 and received several awards including the EFIS Award and the Grand Prix Turpin in Oncology from the French National Academy of Science.

Therapies For Viral Hepatitis By Raymond F. Schinazi

Therapies For Viral Hepatitis By Raymond F. Schinazi If looking for the ebook Therapies for Viral Hepatitis by Raymond F. Schinazi in pdf format, then you have come on to faithful site. We present the